Puma Biotechnology | PBYI - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Biogen USD 2.98B 1.02B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Daiichi Sankyo JPY 489.64B 21.08B 2026-06
Exelixis USD 380.28M 20.8M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Incyte USD 973.64M 4.65B 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Moderna USD 960M 817M 2026-06
Novartis USD 10.2B 912M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Takeda JPY 1.02T 89.68B 2026-06
TG Therapeutics USD 218.66M 48.54M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06